GSE126794
RalA and RalB are potential therapeutic targets in multiple myeloma which mediate cell survival independently of oncogenic RAS
NRAS and KRAS are frequently mutated  oncogenic drivers in multiple myeloma, however, their use as drug targets has not been successful. Hence, we reached out to characterize the role of the RAS-like (RAL) oncogenic signaling cascade and compare transcriptomic changes after knockdown af KRAS and RALA. Overall design: Differential expression experiment after KRAS and RALA knockdown in multiple myeloma cell line.